

**Media Alert****Schering AG, Germany, Announces European Approval of Radioimmunotherapy Zevalin®**

Zevalin® combines the targeting ability of an anti-CD20 monoclonal antibody with the cytotoxic power of beta radiation emitted by the yttrium-90 isotope (Ytracis®) - a pure beta emitter radiopharmaceutical – to effectively destroy lymphoma cells. Radioimmunotherapy with Zevalin® has been shown to be effective in patients who were refractory to antibody treatment thus offering a new prospect for improving the quality of life for these patients.

**What:**

**Journalists are invited to access live webcast to learn more about this novel treatment**

**When:**

**Monday, January 26, 2003 (1:00 P.M. GMT / 2:00 P.M. CET)**

**PANELISTS: David Guy (Moderator)**

Vice President, Strategic Marketing & Business Development, Oncology  
Specialized Therapeutics, Schering AG Group

**Dr. Anton Hagenbeek**

University Medical Center Utrecht (UMCU) (The Netherlands)

**Dr. Tim Illidge**

University of Southampton School of Medicine (United Kingdom)

**WHY:**

NHL is the fifth most common cancer in the world, after breast, prostate, lung and colon cancer. An estimated 230,000 people are now living with this disease in the European Union, with approximately 70,000 new cases diagnosed each year. The average survival for patients with follicular lymphomas has been estimated between six and ten years.

**Login information:**

**Pressrelease today at 8.00**

**URL Address:**

[www.schering.de/scripts/en/50\\_media/2004/events/040126\\_webcast.php](http://www.schering.de/scripts/en/50_media/2004/events/040126_webcast.php)

Instructions: Real Player or Windows Media Player software will be required for the webcast.

Help Line: +49-69-75-085-720

**Dial-in Numbers for conference call:**

US Toll Free Dial in number: 800 218 4007

UK – Local Dial in number: +44(0) 208 515 2334

This media alert has been published by Corporate Communications of Schering AG, Berlin, Germany.